Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California
BOSTON, Aug. 20, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, dedicated to developing and offering novel PET radiopharmaceuticals, has expanded its manufacturing and distribution network for Neuraceq® (florbetaben F-18 injection) in Southern California. This expansion increases access to the broader Southern California area, including San Diego, extending availability of Neuraceq® to imaging centers, physicians, and patients with cognitive impairment. The first dose from a newly-equipped site in Los Angeles was provided on August 13, 2025.
Neuraceq® is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs.
This expansion reflects LMI's ongoing commitment to advancing diagnostic access and improving outcomes for patients affected by Alzheimer's disease in California.
"At LMI, we are focused on expanding geographical access to Neuraceq® for patients and physicians involved in the evaluation of Alzheimer's disease. As the adoption of anti-amyloid therapies continues to grow, the demand for reliable amyloid PET imaging is increasing in parallel. Launching Neuraceq® from Los Angeles is a key milestone in meeting this rising demand. It reflects our ongoing dedication to delivering timely, high-quality diagnostic solutions that align with the evolving needs of neurologists and patients," said Colleen Ruby, US Country Head and Chief Operating Officer, Americas and APAC of LMI, a Lantheus company.
About Neuraceq® (florbetaben 18F)
Indications and Use
NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products.
CONTRAINDICATIONS: None
WARNINGS AND PRECAUTIONS:
Risk for Image Misinterpretation and other Errors: NEURACEQ Risk of Image Misinterpretation and Other Errors: Image interpretation errors have been observed. [see Section 5.1 of the full prescribing information]
Radiation Risk: NEURACEQ, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration in the full prescribing information].
ADVERSE REACTIONS:
The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/application site erythema (1.7%), and injection site irritation (1.1%).
For more information please visit: Neuraceq.com
About Life Molecular Imaging (LMI)
Life Molecular Imaging (LMI), a Lantheus company, is dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit https://life-mi.com.
About LantheusLantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit www.lantheus.com.
ContactsInvestor Relations: Mark KinarneyVice President, Investor Relations978-671-8842ir@lantheus.com
Media: Melissa DownsExecutive Director, External Communications646-975-2533media@lantheus.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/life-molecular-imaging-expands-neuraceq-florbetaben-f-18-injection-production-in-southern-california-302534927.html
SOURCE Life Molecular Imaging
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Californian tests positive for plague after camping in Lake Tahoe area
A California resident tested positive for plague, health officials said. 'The individual is currently under the care of a medical professional and is recovering at home,' El Dorado County officials said in a news release. 'It's believed that the person may have been bitten by an infected flea while camping in South Lake Tahoe area. Health officials are investigating the situation.' The county said it had notified the California Department of Public Health about the case. No other information about the person or their condition was released. Plague is caused by bacteria from bites from fleas that picked up the bacteria from a rodent. However, household pets can bring plague-infected fleas into homes. Human cases of plague are very rare, but can be very serious. Symptoms usually appear following exposure to an infected animal or flea and can include fever, nausea, weakness, swollen lymph nodes or worse. A person in northern Arizona died last month from the plague. At least 15 people have died from plague since 2000, Centers for Disease Control and Prevention data show. However, the disease can be treated effectively with antibiotics if it's diagnosed early. 'Plague is naturally present in many parts of California, including higher elevation areas of El Dorado County,' Kyle Fliflet, El Dorado County's acting director of public health, said in the news release. 'It's important that individuals take precautions for themselves and their pets when outdoors, especially while walking, hiking and or camping in areas where wild rodents are present.' _____
Yahoo
29 minutes ago
- Yahoo
Surf Bio Announces Peer-Reviewed Publication Demonstrating Feasibility of Subcutaneous Delivery of Ultra-Concentrated Biologics
Research conducted by Stanford University and published in Science Translational Medicine shows successful injection of protein formulations exceeding 500 mg/mL PALO ALTO, Calif., Aug. 20, 2025 /PRNewswire/ -- Surf Bio, a biopharmaceutical company transforming the delivery of antibodies and biologics, announced today that a peer-reviewed study conducted by researchers at Stanford University and published in Science Translational Medicine has demonstrated the feasibility of reformulating biologics for subcutaneous delivery at ultra-high concentrations. The study's lead author, Carolyn Jons, Ph.D., and collaborators reported that spray-dried microparticle formulations surpassed 500 mg/mL and were delivered through a standard 27-gauge needle at clinically relevant forces, marking a potential breakthrough in expanding access to infusion-only therapies. The paper, entitled, "Glassy Surfactants Enable Ultra-High Concentration Biologic Therapeutics," may be accessed via the following URL: "The research addresses one of the most persistent challenges in drug delivery: how to administer high-dose biologic therapies without the need for intravenous infusion," stated Dr. Jons. "Many existing protein-based therapies require hospital or clinic-based infusions due to their large volume, instability, or reconstitution requirements. This study describes a spray-drying process that converts protein formulations into microparticles suspended in a non-solvent liquid carrier, resulting in a stable, ready-to-inject solution that meets the viscosity and force thresholds for subcutaneous administration." "This research provides a critical foundation for our work at Surf Bio and highlights the significant potential of our SnapShot™ technology," said Bryan Mazlish, CEO of Surf Bio. "We're leveraging this licensed platform to help unlock subcutaneous administration for therapies that have historically required IV infusion. Our goal is to translate this innovation into ready-to-inject, patient-friendly formulations that reduce burden on the healthcare system while enabling self-administration at home." Importantly, the platform utilizes a polymer excipient that improves stability during spray drying and enhances the injectability of the final formulation. In preclinical models, these microparticles were shown to maintain protein activity and structure, achieving doses well beyond those currently accessible with drug products approved for subcutaneous delivery. The technology does not require any specialized delivery device and can be used with commercially available autoinjectors and standard fill-finish processes. About Surf Bio:Surf Bio is a biopharmaceutical company transforming the delivery of antibodies and biologics via its SnapShot™ technology platform. Powered by the Company's proprietary polymer, SnapShot enables the development of ultra-high concentration formulations of monoclonal antibodies (mAbs) and biologics that can be administered using a single, standard autoinjector shot. To date, in-vitro and in-vivo safety and efficacy data have demonstrated that SnapShot enables drug developers to produce very high concentration, subcutaneous formulations of novel mAbs and biologics. Surf Bio was launched by the founders of Bigfoot Biomedical and AGC to commercialize a breakthrough drug delivery technology developed in the Appel lab at Stanford University. For more information about Surf Bio, visit Contact for Surf Bio:Tiberend Strategic Advisors, Reissereiss@ View original content to download multimedia: SOURCE Surf Bio, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Officials sound alarm over first-of-its-kind infestation in major US city: 'It can threaten public health and diminish quality of life'
Officials sound alarm over first-of-its-kind infestation in major US city: 'It can threaten public health and diminish quality of life' An invasive species of mosquito has been discovered in one of the nation's most populous counties, and officials warn it could transmit serious diseases. What's happening? Officials with the Alameda County Mosquito Abatement District have detected the Aedes aegypti mosquito, KTVU reported. The mosquitoes, which can transmit diseases such as dengue, Zika, and yellow fever, were found in Livermore, a town on the San Francisco Valley's eastern edge. Aedes aegypti is considered invasive in California and has been spotted in 26 counties, officials with the district say. It is especially aggressive in the daytime and often bites people's ankles. "If Aedes aegypti becomes established in Alameda County, it can threaten public health and diminish quality of life," the agency said in a news release. Why do mosquitoes matter? All invasive species are a concern to their particular ecosystems. When a species is introduced to a foreign environment, it runs the risk of becoming invasive — spreading quickly and outcompeting native plants or wildlife for resources including food and water. It's particularly concerning when the species in question is a mosquito. Because of the diseases they transmit, mosquitoes have been called "the world's deadliest animal." Aedes aegypti, in particular, can spread easily because its eggs can survive for more than a year without water. And human actions are making it easier for mosquitoes to reach new areas and thrive once there. The pollution caused by burning fossil fuels has heated the planet to levels never seen before. And because mosquitoes thrive in warm climates, these higher temperatures have allowed them to be found in previously unthinkable places, such as Finland. What's being done about these mosquitoes? The mosquito abatement officials say their goal is to ensure Aedes aegypti doesn't establish a foothold in Alameda County. To accomplish that, they have been conducting door-to-door checks in two areas where the mosquito was detected. "The quickest way to prevent this annoying and potentially dangerous mosquito species from becoming established is to act now," abatement district general manager Ryan Clausnitzer told KTVU. "We urge residents to grant yard access so we can ensure no one is accidentally breeding mosquitoes." California health officials also encourage people to apply mosquito repellent and to dump and drain standing water — no matter how small the amount — to help prevent the species from spreading. Do you worry about the quality of the air inside your home? Yes — often Yes — but only sometimes Only when it's bad outside No — I never do Click your choice to see results and speak your mind. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the the daily Crossword
